If your gene report says you are a CYP2B6 intermediate metabolizer, it means your body clears some medicines more slowly than average. This guide explains the result, the drugs it affects most and how to talk it through with your prescriber.
On this page
The role of the CYP2B6 enzyme in drug metabolism is crucial, especially for individuals undergoing HIV treatment. CYP2B6 intermediate metabolizers, who possess a moderate level of enzyme activity due to genetic polymorphisms, face unique challenges when prescribed HIV medications metabolized by this enzyme, such as efavirenz. Efavirenz, a long-used antiretroviral drug, relies on CYP2B6 for its metabolism.
Intermediate metabolizers often exhibit slower drug clearance compared to normal metabolizers, which can lead to elevated drug levels in the bloodstream. This increases the risk of adverse effects, including central nervous system (CNS) toxicity, characterised by dizziness, vivid dreams, insomnia, and, in severe cases, psychiatric disturbances.
Furthermore, sustained high plasma concentrations may exacerbate drug toxicity while potentially reducing adherence to treatment. Pharmacogenetic testing can help identify intermediate metabolizers, enabling clinicians to tailor efavirenz dosing or opt for alternative therapies to optimize efficacy and minimize side effects.
CYP2B6: An Overview
CYP2B6 is an important enzyme within the cytochrome P450 superfamily, primarily expressed in the liver and to a lesser extent in the brain, kidneys, and lungs. CYP2B6 activity is influenced by genetic polymorphisms, leading to variations in how individuals metabolize drugs. Variants in the CYP2B6 gene, such as CYP2B6 516G>T and CYP2B6 983T>C, are known to alter enzyme function. These polymorphisms may result in decreased or increased enzyme activity, making patients intermediate, poor, or ultrarapid metabolizers of drugs processed by CYP2B6.
Importantly, CYP2B6-mediated drug metabolism significantly impacts therapeutic outcomes and the risk of side effects, emphasizing its crucial role in personalized medicine.
The CYP2B6 enzyme metabolizes many drugs, including antidepressants, chemotherapeutic agents, and anaesthetics.
Antidepressants
Bupropion: Metabolised by CYP2B6, Bupropion is an antidepressant and smoking cessation aid marketed under different brand names such as Wellbutrin, Wellbutrin SR, Wellbutrin XL, Zyban, and bupropion hydrochloride.
Chemotherapeutic agents
- Cyclophosphamide: Activated mainly by the cytochrome P450 enzyme CYP2B6, with help from other CYP enzymes, Cyclophosphamide (Cytoxan) is an antineoplastic agent used mainly to treat cancers such as lymphoma, leukemia and breast cancer. It is also used for some serious autoimmune conditions, such as severe lupus nephritis and vasculitis.
- Ifosfamide: An antineoplastic agent primarily metabolized by CYP3A4, however, CYP2B6 plays a secondary role in its breakdown in the body.
Anesthetics
- Propofol: During the anaesthesia, an anaesthetic that prevents pain and discomfort during medical procedures, which is administered intravenously. It is cleared mainly by glucuronidation through the enzyme UGT1A9, with CYP2B6 playing a smaller role. Research has explored CYP2B6 genotype and propofol dosing, but genotype-guided propofol dosing is not routine practice.
- Ketamine: An anaesthetic that is also administered as an anti-depressant (however is not suitable for everyone suffering from depression) is metabolised mainly by CYP2B6 and CYP3A4.
Other drugs
- Efavirenz: An antiretroviral that CYP2B6 metabolizes
- Nevirapine: An antiretroviral that CYP2B6 metabolizes
- Pethidine: A synthetic opioid that CYP2B6 metabolizes
- Methadone: A synthetic opioid that CYP2B6 metabolizes
- Selegiline: An anti-Parkinsonian drug that CYP2B6 metabolizes
What Are Enzymes and the CYP2B6 Family?
Enzymes are biological catalysts that accelerate chemical reactions in the body, playing important roles in processes such as digestion and metabolism. The cytochrome P450 (CYP) family comprises enzymes responsible for metabolizing various substances, including drugs. CYP2B6 is a significant member of this family, involved in the metabolism of several clinically important medications.
Genotyping and Its Importance
Genotyping involves analyzing an individual’s DNA to identify genetic variations that affect enzyme activity. Variations in the CYP2B6 gene can classify individuals into different metabolizer statuses:
- Poor Metabolizers: Significantly reduced enzyme activity.
- Intermediate Metabolizers: Moderate enzyme activity.
- Normal (Extensive) Metabolizers: Standard enzyme activity.
- Rapid Metabolizers: Increased enzyme activity.
- Ultrarapid Metabolizers: Substantially increased enzyme activity.
Identifying an individual’s metabolizer status through genotyping can guide personalized medication strategies, ensuring optimal efficacy and minimizing adverse effects.
Efavirenz Effects on Intermediate Metabolizers: HIV Management
Efavirenz, a non-nucleoside reverse transcriptase inhibitor (NNRTI), is commonly used in antiretroviral therapy for HIV. The metabolism of efavirenz is significantly influenced by CYP2B6 activity. Intermediate metabolizers may experience higher plasma concentrations of the drug, leading to an increased risk of side effects such as dizziness, insomnia, and vivid dreams. Conversely, poor metabolizers might face even higher risks due to slower drug clearance.
Efavirenz lowers the amount of HIV (human immunodeficiency virus) in the blood, but it does not cure HIV. It is always used in combination with other HIV medicines, and your HIV care team decides which combination and dose suit you best.
Can Pharmacogenetic Testing Help?
Pharmacogenetic tests analyze your genetic variations to predict how you will respond to certain medications, such as a CYP2B6 Intermediate Metabolizer may be at higher risk of adverse drug effects as compared to a normal metabolizer. A test report from RPh labs clearly shows how you may react to 240+ medications, helping doctors tailor your medication per your unique DNA. Thus, minimizing the adverse drug reactions and improving treatment outcomes.
What a CYP2B6 intermediate metabolizer result means
Your report gives CYP2B6 a phenotype. Each person has two copies of the CYP2B6 gene. Labs look at which version (star allele) you carry on each copy and give each one a function: normal, decreased, no function or increased. Your two copies together set your phenotype.
A CYP2B6 intermediate metabolizer usually has one normal-function copy and one decreased or no-function copy, for example *1/*6 or *1/*18. Some people with one increased-function copy and one decreased copy, such as *4/*6, are also grouped here. Overall enzyme activity is lower than normal, but not as low as in a poor metabolizer.
In daily life you will not feel any different. The result only matters when you take a medicine that relies on CYP2B6, where slower clearance can raise drug levels. For many CYP2B6 drugs the standard dose is still fine, and your prescriber decides whether any change is needed.
The CYP2B6 *6 allele and other common variants
The CYP2B6 *6 allele is the most widely studied decreased-function version of the gene. It is defined by two DNA changes, 516G>T and 785A>G, and the 516G>T change reduces how much working enzyme the liver makes. The CYP2B6 *6 allele is common in many populations around the world.
Other alleles you may see on a report include:
- *1: the normal-function reference version.
- *18: a no-function version, defined by the 983T>C change and found more often in people of African ancestry.
- *4: an increased-function version.
- *9: a decreased-function version that shares the 516G>T change.
The full list of CYP2B6 alleles and their definitions is kept by PharmVar. Your CYP2B6 genotype is set at birth and does not change, so a single test result stays valid for life.
Efavirenz dosing guidance by CYP2B6 genotype
Efavirenz is the medicine with the clearest CYP2B6 guidance. The usual adult dose is 600 mg once a day. Because slower CYP2B6 activity raises efavirenz blood levels, CPIC guidelines give genotype-based suggestions for efavirenz dosing.
- Normal, rapid or ultrarapid metabolizers: start at the standard 600 mg daily dose.
- CYP2B6 intermediate metabolizer: consider starting at a lower dose of 400 mg daily.
- CYP2B6 poor metabolizer: consider starting at 400 mg or 200 mg daily.
The goal is to keep the drug working against HIV while lowering the chance of side effects such as dizziness, vivid dreams, trouble sleeping and trouble concentrating. Some clinics also measure efavirenz blood levels to fine-tune the dose.
Efavirenz is used less often as a first choice in the United States than it once was, but many people still take it, often in combination pills. Never change your HIV medicine on your own. Efavirenz dosing decisions belong with your HIV care team, who will also watch your viral load.
CYP2B6 poor metabolizer vs intermediate: how the risks compare
A CYP2B6 poor metabolizer has two decreased or no-function copies, such as *6/*6, *6/*18 or *18/*18. Enzyme activity is the lowest of all groups, so drug levels of CYP2B6 medicines tend to be highest.
Compared with a CYP2B6 intermediate metabolizer, a poor metabolizer is more likely to have side effects at a standard efavirenz dose, and guidelines suggest the larger dose reduction. Intermediate metabolizers sit between normal and poor, so their risk is moderate and the suggested change is smaller.
Keep in mind that your phenotype is only part of the story. Age, liver function, body size, other medicines and how consistently you take your doses all shape drug levels. Two people with the same CYP2B6 genotype can still respond differently, which is why guidance speaks of what to consider rather than fixed rules.
If you already take efavirenz and feel well, a CYP2B6 poor metabolizer or intermediate result does not mean something is wrong. Many people tolerate the standard dose. The result simply gives your care team another piece of information if side effects appear, if a dose change is being discussed, or if a new medicine is added.
Other drugs a CYP2B6 genotype can affect
Beyond HIV care, CYP2B6 helps process several common medicines. The evidence is weaker for most of these than for efavirenz, so your result is a helpful clue rather than a firm instruction.
- Sertraline: the 2023 CPIC guideline for SSRIs includes CYP2B6 for sertraline. For people with reduced CYP2B6 activity, such as poor metabolizers, it suggests prescribers consider a lower starting dose or slower dose increases.
- Methadone: CYP2B6 helps clear methadone, and studies link the CYP2B6 *6 allele to higher methadone levels. CPIC has not issued a genotype-based dosing recommendation, so dose changes rely on clinical monitoring.
- Bupropion: CYP2B6 converts bupropion into its main active product, hydroxybupropion. There is no formal genotype-based dosing guidance yet.
- Ketamine: CYP2B6 is a main pathway, and research is ongoing into how genotype affects its effects.
Our medication list shows each drug by gene, and the FDA table of pharmacogenomic biomarkers shows which drug labels mention CYP2B6.
Drug interactions that change CYP2B6 activity
Other medicines can raise or lower CYP2B6 activity on top of your genes. This means a CYP2B6 intermediate metabolizer may act more like a poor metabolizer, or more like a normal one, depending on what else they take.
- Inhibitors slow CYP2B6. Examples include the antiplatelet drugs clopidogrel and ticlopidine.
- Inducers speed CYP2B6 up. Examples include rifampin and some seizure medicines such as carbamazepine.
- Efavirenz itself gradually increases CYP2B6 activity over the first weeks of treatment, which is one reason levels can shift early on.
Always give your prescriber and pharmacist a full list of prescriptions, over-the-counter products and supplements. They can check for these interactions alongside your CYP2B6 genotype and decide together with you whether anything should change.
Getting a CYP2B6 genotype test at home
A CYP2B6 genotype test only needs a DNA sample, and your current medicines do not affect the result. The RPh Labs at-home PGx kit uses a cheek swab and includes CYP2B6 in a 20-gene panel alongside CYP2C19, CYP2D6, CYP3A4 and others, reported against 240+ medications.
The process is simple:
- Order the kit. It ships within one business day, with free shipping both ways.
- Swab the inside of your cheeks and mail the sample back in the prepaid mailer.
- Get your report 7 to 10 business days after the sample reaches our CLIA-certified lab in Dallas, Texas.
- Book your free pharmacist consultation to go over the results.
Every report is reviewed by a PharmD pharmacist and updated when guidelines change. See how it works for more detail, or check our insurance page if you want to use your plan.
Questions to ask your prescriber about your result
Bring your full report to your next visit, not just the phenotype line. Your prescriber or HIV care team can match it to your current medicines and your health history.
- Do any of my current medicines depend on CYP2B6?
- If I start efavirenz, would you consider a lower starting dose for me?
- Do any of my other medicines speed up or slow down CYP2B6?
- Should my drug levels be checked after starting a new medicine?
- Can you record my CYP2B6 result in my chart for future prescriptions?
If you notice new dizziness, sleep problems, unusual dreams or mood changes after starting a CYP2B6 medicine, tell your prescriber promptly. Seek urgent care for thoughts of self-harm or severe confusion. Do not stop your medicine on your own, especially HIV medicine, because missed doses can let the virus become resistant.
Conclusion
The CYP2B6 enzyme plays a key role in the metabolism of numerous drugs, including antidepressants and HIV medications, such as bupropion and Efavirenz. CYP2B6 Intermediate Metabolizers may show slower drug clearance, resulting in adverse drug reactions. Genetic differences influencing CYP2B6 enzyme activity in our body can significantly impact drug effectiveness and safety. Pharmacogenetic testing, by giving insights into your DNA (genetic makeup) offers a way to personalised medicine, allowing treatment plans that align with an individual’s genetic profile.
Tailored medications may not only save you from trial and error, but they may also be more effective and save time.
CYP2B6 intermediate metabolizer FAQ
Is being a CYP2B6 intermediate metabolizer common?
Yes. Because the CYP2B6 *6 allele is common in many populations, carrying one reduced copy is a frequent result. It is not a disease and causes no symptoms on its own. It only matters when you take a medicine that relies on CYP2B6, where your prescriber may consider your result.
What efavirenz dose is suggested for intermediate metabolizers?
CPIC guidance suggests prescribers consider starting efavirenz at 400 mg daily instead of the standard 600 mg for intermediate metabolizers, and 400 mg or 200 mg for poor metabolizers. The goal is fewer side effects while keeping HIV controlled. Your HIV care team makes the final decision.
Does the CYP2B6 *6 allele affect methadone?
Studies link the CYP2B6 *6 allele to higher methadone levels, but CPIC has not issued a genotype-based dosing recommendation for methadone. Dosing is guided by careful clinical monitoring. Share your result with your prescriber, who can weigh it along with your response and other medicines.
Can a CYP2B6 poor metabolizer take bupropion?
There is no formal genotype-based dosing guidance for bupropion, so a poor metabolizer result does not by itself rule it out. CYP2B6 does help turn bupropion into its active form, so your prescriber may watch your response a little more closely. Never start or stop a medicine without them.
Will my CYP2B6 result change over time?
No. Your CYP2B6 genotype is inherited and stays the same for life, so you only need to test once. Your real-world activity can shift with other medicines that speed up or slow down the enzyme, and guideline advice can be updated, so keep your report handy.
Is CYP2B6 included in the RPh Labs panel?
Yes. CYP2B6 is one of 20 genes on the RPh Labs panel, along with CYP2C19, CYP2D6, SLCO1B1 and others. The at-home cheek swab kit is $299 self-pay, is HSA and FSA eligible, and includes a free pharmacist consultation. Insurance, including Medicare, is also accepted.
Leave a Reply